US govt faces calls to green-light prostate cancer drug generics
Annual global sales of Pfizer and Astella blockbuster drug reach roughly $5 billion | Nonprofits argue the drug is sold at a price three to six times higher in the US than it’s priced in other similar high-income countries | Move to curb drug prices follows controversial march-in rights plan.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
17 August 2023 Judges uphold PTAB decision invalidating Incept patents related to use of biodegradable filler in radiation treatment | Swedish firm Palette had challenged patents through inter partes review.
23 March 2023 NIH rejects petition to use “march-in” rights to allow cheaper competition | Xtandi is “widely available” to public, federal agency says.